Formulations for wound therapy
View Patent ↗The present invention relates to novel formulations comprising a dry powder fibrin sealant comprised of a mixture of fibrinogen and/or thrombin, for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention.
1. A pharmaceutical composition comprising an absorbable carrier of a biocompatible, biodegradable polymer and microparticles comprising fibrinogen in an amount of from about 0.1-15 mg/cm2 and/or microparticles comprising thrombin in an amount of from about 0.01 to 500 IU/cm2, wherein the microparticles further comprise a glassy carrier, and wherein the microparticles are homogeneously attached to said absorbable carrier.
2. The pharmaceutical composition according to claim 1 , wherein the composition comprises a mixture of microparticles comprising fibrinogen and microparticles comprising thrombin.
3. The pharmaceutical composition according to claim 2 , wherein the glassy carrier of the microparticles comprises trehalose.
4. The pharmaceutical composition according to claim 1 , wherein the absorbable carrier is flexible or porous, and the composition optionally further comprises a plasticizer, binder or viscosifying agent.
5. The pharmaceutical composition according to claim 4 , wherein the absorbable carrier is both flexible and porous.
6. The pharmaceutical composition according to claim 1 wherein the absorbable carrier comprises a biocompatible polymer selected from the group consisting of polysaccharides, albumin, a cellulose, methylcellulose, alkylhydroxyalkyl cellulose, hydroxyalkyl cellulose, cellulose sulfate, salts of carboxymethyl cellulose, carboxymethyl cellulose, carboxyethyl cellulose, oxidised cellulose; gelatins or collagen, such as a collagen-sponge, chitin, carboxymethyl chitin, hyaluronic acid, salts of hyaluronic acid, alginate, alginic acid, propylene glycol alginate, glycogen, dextran, dextran sulfate, curdlan, pectin, pullulan, xanthan, chondroitin, chondroitin sulfates, carboxymethyl dextran, heparin, heparin sulfate, heparan, heparan sulfate, dermatan sulfate, keratan sulfate, carrageenans, starch, amylose, amylopectin, poly-N-glucosamine, poly-N-acetyl glucosamine, polymannuronic acid, polyglucuronic acid, polyguluronic acid; chitosan, chitin, chitin-glucan, chitosan-glucan, carboxymethyl chitosan, chitosan salts, chitosan derivatives thereof, and any combinations thereof; a polyurethane, oxidised polysaccharides, and derivatives or combinations of any of the above.
7. The pharmaceutical composition according to claim 1 , wherein the composition is provided as a dry adhesive coating, aerosol, dry aerosol, pump spray, medical compress; film; coated plaster; medicated sponge or surgical patch, hemostatic fleece; hemostatic pad; gauze; salve, semi-gel, gel, foam, paste, suspension, ointment, emulsion, moldable form, nasal plug, surgical dressing, wound packing, bandage, swab, catheter, fibre optic, syringe, pessary, suppository, or suspension in a liquid or non-aqueous liquid.
8. The pharmaceutical composition according to claim 6 , wherein the absorbable carrier comprises chitosan, or derivative or salt or co-polymer thereof; gelatin, collagen or a polyurethane.
9. The pharmaceutical composition according to claim 1 wherein the fibrinogen or thrombin are recombinant, human, purified from a natural source, or transgenic.
10. The pharmaceutical composition according to claim 1 for hemostasis, tissue sealing or tissue gluing.
11. A method of treating a wound or reducing bleeding at a haemorrhaging site, comprising administering to the wound or haemorrhaging site a pharmaceutical composition according to claim 1 .
12. The method according to claim 11 , wherein said treatment results in a time to hemostasis of less than about 10 minutes when administered to a wound or haemorrhaging site which exhibits a bleeding rate of greater than about 30 g/minute.
13. The method according to claim 11 , wherein the absorbable carrier consists essentially of a biocompatible, biodegradable polymer selected from a cellulose, polyurethane, gelatin or collagen, such as a collagen-sponge, or a chitosan, and amorphous fibrinogen or amorphous thrombin, and the treatment is for tissue sealing, tissue gluing or hemostasis.
14. The method according to claim 13 , wherein the amorphous fibrinogen or amorphous thrombin exhibit a degree of crystallinity of at most about 10% by weight of the microparticle population in the carrier.
15. The method according to claim 13 wherein the treatment is for the topical treatment of a wound, and the wound is selected from the group consisting of a) minor abrasions, cuts, scrapes, scratches, burns, sunburns, ulcers, internal venous bleeding, external venous bleeding, and b) surgical interventions selected from gastrointestinal surgery, surgery on parenchymal organs; surgical interventions in the ear, nose and throat area (ENT), cardiovascular surgery, aesthetic surgery, spinal surgery, neurological surgery; lymphatic, biliary, and cerebrospinal (CSF) fistulae, air leakages during thoracic and pulmonary surgery, thoracic surgery, orthopaedic surgery; gynaecological surgical procedures; vascular surgery and emergency surgery, liver resection, and soft tissue injury or surgery.
16. The method according to claim 15 , wherein the pharmaceutical composition is topically applied to a traumatic injury in the battle field, a wound or during or after surgery.
17. The pharmaceutical composition according to claim 9 , wherein the recombinant fibrinogen is HMW fibrinogen or alpha-extended fibrinogen.
18. A pharmaceutical composition comprising:
an absorbable carrier comprising a biocompatible, biodegradable polymer; and
microparticles comprising fibrinogen in an amount of from about 0.1-15 mg/cm 2 and/or microparticles comprising thrombin in an amount of from about 0.01 to 500 IU/cm 2 attached in a homogenous distribution to said absorbable carrier,
wherein the microparticles further comprise a glassy carrier.
19. A pharmaceutical composition comprising: an absorbable carrier comprising a biocompatible, biodegradable polymer; and microparticles comprising fibrinogen in an amount of from about 0.1-15 mg/cm2 and microparticles comprising thrombin in an amount of from about 0.01 to 500 IU/cm2 homogeneously attached to said absorbable carrier, wherein the microparticles further comprise trehalose.